ArticleBioinformation2026
Sertraline-induced fetotoxicity in mice: Protective effects of vitamin E on foetal growth and organ histology.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sertraline, a selective serotonin reuptake inhibitor (SSRI), is widely used for treating depression and anxiety disorders, including during pregnancy, yet its potential effects on fetal development remain a concern. Oxidative stress is considered a possible mechanism for drug-induced developmental toxicity, suggesting antioxidant supplementation may mitigate such effects. Therefore, it is of interest to assess the fetotoxic potential of sertraline and the protective role of Vitamin E in eighteen pregnant Swiss albino mice divided into control, sertraline-treated (60 mg/kg/day) and sertraline + Vitamin E (100 mg/kg/day) groups. Treatments were given orally from gestational day 6-15, followed by evaluation of fetal growth and organ histopathology on day 19. Sertraline exposure significantly reduced fetal number, weight, crown-rump length and placental metrics, with marked cardiac, hepatic and renal alterations, while Vitamin E co- administration partly ameliorated these effects. Thus, we show oxidative stress in sertraline-induced fetal toxicity and demonstrating the partial protective potential of Vitamin E supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.